All In Biotech

BLA 103950 · Biovitrum Ab

Kineret

Anakinra · Subcutaneous · Interleukin-1 Receptor Antagonist

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Nov 14, 2001

Approved uses

6

Original approval plus efficacy supplements

Registered trials

188

40 Phase 3, 18 recruiting

FAERS reports

16,900

11,721 serious, 1,576 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 3, 2026.

KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) ( 1.1 ) Cryopyrin-Associated Periodic Syndromes (CAPS) Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) ( 1.2 ) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) ( 1.3 ) 1.1 Active Rheumatoid Arthritis KINERET is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs). KINERET can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents [see Warnings and Precautions ( 5.2 )]. 1.2 Cryopyrin-Associated Periodic Syndromes (CAPS) KINERET is indicated for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). 1.3 Deficiency of Interleukin-1 Receptor Antagonist (DIRA) KINERET is indicated for the treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

Mechanism: KINERET blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. IL-1 has a broad range of activities including cartilage degradation by its induction of the rapid loss of proteoglycans, as well as stimulation of bone resorption. The levels of the naturally occurring IL-1Ra in synovium and...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 2020 Supplement 5189 · Efficacy · priority review OrphanLabelLetter
  • Dec 21, 2012 Supplement 5136 · Efficacy · priority review LetterLabel
  • Dec 15, 2006 Supplement 5064 · Efficacy
  • Feb 22, 2006 Supplement 5061 · Efficacy
  • Aug 22, 2003 Supplement 5019 · Efficacy Letter
  • Nov 14, 2001 Original approval · Type 1 - New Molecular Entity NovelOrphanPatient Package InsertLabelReview
3 products under this application
  • KINERET · ANAKINRA 25MIU/VIAL · VIAL, SUBCUTANEOUS · Prescription
  • KINERET · ANAKINRA 10MIU/VIAL · VIAL, SUBCUTANEOUS · Prescription
  • KINERET · ANAKINRA 18MIU/VIAL · VIAL, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Anakinra" as an intervention, any sponsor and status, largest first.

All 188 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use5,297
  • drug ineffective4,355
  • condition aggravated1,743
  • pain1,603
  • rheumatoid arthritis1,556
  • arthralgia1,207
  • joint swelling1,192
  • pyrexia1,189
  • drug intolerance1,168
  • injection site pain1,047
  • rash996
  • nausea961

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004118
200558
2006111
2007253
2008276
200988
201075
201180
2012109
2013117
2014107
2015186
2016563
2017864
20181,078
20191,586
20203,066
20211,624
20221,845
20231,210
20241,289
20251,182
20261,015

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kineret (Anakinra)

2024 spending

$32.1M

Beneficiaries

921

5,321 claims

Per beneficiary

$34,895

$291.55 per unit

View as table
YearSpending
2020$19,061,039
2021$21,497,994
2022$23,620,004
2023$28,024,001
2024$32,138,063

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 344 on PubMed

Sponsor: Biovitrum Ab

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.